Posted by Michael Wonder on 22 Feb 2021
Celsion Corporation receives FDA fast track designation for GEN-1 in advanced ovarian cancer
22 February 2021 - Designation provides potential for an expedited regulatory review..
Celsion Corporation today announced that it has received fast track designation from the U.S. FDA for GEN-1, its DNA-mediated interleukin-12 (IL-12) immunotherapy currently in Phase II development for the treatment of advanced ovarian cancer.
GEN-1 was designed using TheraPlas, Celsion's proprietary, synthetic, non-viral nanoparticle delivery system platform.
